• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RNTX

    Rein Therapeutics Inc.

    Subscribe to $RNTX
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2017

    Exchange: NASDAQ

    Recent Analyst Ratings for Rein Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    1/28/2025$8.00Buy
    Rodman & Renshaw
    See more ratings

    Rein Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

      1/28/25 7:16:42 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Rein Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

      Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas, May 27, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.

      5/27/25 7:00:00 AM ET
      $IQV
      $RNTX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

      Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (IPF) Company recently initiated RENEW Phase 2 trial evaluating the safety, tolerability and efficacy of LTI-03 in IPF AUSTIN, Texas, May 19, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company and its collaborators presented two posters supporting the potential therapeutic effectiveness of LTI-03 in idiopathic pulmonary fibros

      5/19/25 4:51:00 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) initiated with topline interim data expected in the first half of 2026 Two abstracts accepted to the American Thoracic Society (ATS) 2025 International Conference Cash runway extended following previously announced warrant transactions and private placement AUSTIN, Texas, May 15, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended Ma

      5/15/25 4:09:00 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

      The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed a positive trend in seven out of eight biomarkers evaluated in Cohort 2, with five showing dose dependence and four showing statistically significant improvement in the combined Cohort 1 and 2 data set AUSTIN, Texas, May 12, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the RENEW Phase 2 trial of its lead asset, LTI-03,

      5/12/25 7:00:00 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

      AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis (IPF).

      5/1/25 7:00:00 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

      AUSTIN, Texas, April 30, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at The Citizens Life Sciences Conference 2025 on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY. A live webcast of the event can be accessed at https://ir.reintx.com/events-presentations. A replay of the webcast will be

      4/30/25 4:05:00 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

      AUSTIN, Texas, April 28, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA. Details of the poster presentation are as follows: Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD

      4/28/25 7:00:00 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

      AUSTIN, Texas, April 23, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the U.S. Patent and Trademark Office (USPTO) granted two new patents related to Rein's lead product candidate, LTI-03, a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling, which is administered through dry powder inhalation.

      4/23/25 7:00:00 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

      Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) AUSTIN, Texas, April 15, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines.

      4/15/25 7:00:00 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF patients demonstrated dose dependent effects in five biomarkers evaluated, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set AUSTIN, Texas, April 7, 2025 /PRNewswire/ -- Rein Therapeutics, Inc. (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fib

      4/7/25 4:17:00 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Rein Therapeutics Inc. SEC Filings

    See more
    • SEC Form EFFECT filed by Rein Therapeutics Inc.

      EFFECT - Rein Therapeutics, Inc. (0001420565) (Filer)

      5/23/25 12:15:13 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Rein Therapeutics Inc.

      S-3 - Rein Therapeutics, Inc. (0001420565) (Filer)

      5/16/25 9:23:38 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Rein Therapeutics Inc.

      8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

      5/15/25 4:18:26 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rein Therapeutics Inc.

      10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)

      5/15/25 4:06:58 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Rein Therapeutics Inc.

      424B5 - Rein Therapeutics, Inc. (0001420565) (Filer)

      5/15/25 4:01:28 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Rein Therapeutics Inc.

      DEFA14A - Rein Therapeutics, Inc. (0001420565) (Filer)

      5/12/25 4:32:36 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Rein Therapeutics Inc.

      DEF 14A - Rein Therapeutics, Inc. (0001420565) (Filer)

      5/12/25 4:30:00 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Rein Therapeutics Inc.

      10-K/A - Rein Therapeutics, Inc. (0001420565) (Filer)

      4/30/25 5:27:49 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

      4/22/25 8:58:51 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

      4/17/25 4:14:46 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care